AZN

Astrazeneca plc

Feb 02 • 04:00PM ET

188.41

+1.31 0.70 %

Healthcare • Drug Manufacturers - General • United Kingdom • NYSE

Today, 7:00 AMAstraZeneca reports that the FDA has accepted and granted Priority Review to its and Daiichi Sankyo’s supplemental BLA for Datroway (datopotamab deruxtecan) in unresectable or metastatic triple-negative breast cancer, with a PDUFA decision expected in the second quarter of 2026.

Held by: PVAL AVDE AVDE DIHP DFIC PPH PPH FVD DFAX APIE

Scroll to Statements

Index	-	P/E	31.28	EPS (ttm)	6.02	Insider Own	4.81%	Shs Outstand	1.55B	Perf Week	5.23%
Market Cap	292.12B	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.48B	Perf Month	7.36%
Enterprise Value	316.66B	PEG	-	EPS next Q	-	Inst Own	53.77%	Short Float	-	Perf Quarter	12.83%
Income	9.40B	P/S	5.03	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	34.33%
Sales	58.13B	P/B	6.37	EPS next Y	-	ROA	8.57%	Short Interest	-	Perf YTD	7.36%
Book/sh	29.60	P/C	35.70	EPS next 5Y	-	ROE	21.70%	52W High	195.00 -3.38%	Perf Year	43.91%
Cash/sh	5.28	P/FCF	22.30	EPS past 3/5Y	285.86% 34.63%	ROIC	13.06%	52W Low	122.26 54.11%	Perf 3Y	57.09%
Dividend Est.	-	EV/EBITDA	16.44	Sales past 3/5Y	12.64% 17.27%	Gross Margin	73.23%	Volatility	3.68% 2.65%	Perf 5Y	85.83%
Dividend TTM	3.16 (1.68%)	EV/Sales	5.45	EPS Y/Y TTM	44.64%	Oper. Margin	21.86%	ATR (14)	6.86	Perf 10Y	311.38%
Dividend Ex-Date	Aug 08, 2025	Quick Ratio	0.69	Sales Y/Y TTM	13.52%	Profit Margin	16.17%	RSI (14)	54.52	Recom	-
Dividend Gr. 3/5Y	2.80% 2.47%	Current Ratio	0.88	EPS Q/Q	77.36%	SMA20	1.49%	Beta	0.39	Target Price	-
Payout	69.15%	Debt/Eq	0.71	Sales Q/Q	11.99%	SMA50	2.95%	Rel Volume	1823.18	Prev Close	187.10
Employees	94300	LT Debt/Eq	0.57	Earnings	Feb 10 BMO	SMA200	19.16%	Avg Volume	58.37K	Price	188.41
IPO	Oct 17, 2003	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.80% 2.79%	Trades		Volume	3,228,008	Change	0.70%

Today 07:00AM	DATROWAY (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy (Business Wire)
06:55AM	AstraZeneca Responds With Data After FDA Delays Lupus Drug Shot (Benzinga)
04:34AM	AstraZeneca PLC (NASDAQ:AZN) Announces Strategic Collaboration Agreement With CSPC Pharmaceuticals (Insider Monkey)
02:42AM	AstraZenecas Initial Application for Lupus Injection Turned Down by FDA (The Wall Street Journal)
Feb-02-26 02:15PM	Should You Buy the Dip in IonQ Stock? (Barchart)
02:04PM	Loading…
02:04PM	US and India reach trade deal, Astrazeneca shares move to NYSE (Yahoo Finance Video)
12:29PM	AstraZeneca Moves to NYSE as $50 Billion US Investment Plan Takes Focus (GuruFocus.com)
11:00AM	AZN Obesity Pipeline to Get a Boost From Deal With China's CSPC (Zacks)
10:01AM	AstraZeneca Shares Start Trading in US After Listing Upgrade (Bloomberg)
07:00AM	AstraZeneca begins trading on the New York Stock Exchange (Business Wire)
Jan-30-26 12:28PM	Health Care Roundup: Market Talk (The Wall Street Journal)
11:11AM	Block quotes in PNR test (Test Provider for Finance)

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company's history roots back to the year 1913 when Astra business was formed. AstraZeneca was founded in 1999 through the merger of Astra AB and Zeneca Group PLC. The company is headquartered in Cambridge, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AZN

Astrazeneca plc

Upgrade your FINVIZ experience